CAS 1422284-15-8

Tenofovir Disoproxil Related Compound G (O-(Isopropoxycarbonyloxymethyl)-O-isopropyl-{(R)-[1-(6-amino-9H-purin-9-yl)propan-2-yloxy]}methylphosphonate) fumarate)

CAS : 1422284-15-8

Compounds containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure, nesoi

Formule : C₁₇H₂₈N₅O₇P·C₄H₄O₄

Couleur et forme : Powder

Masse moléculaire : 445.17264

Ref: 45-1643678

Tenofovir Disoproxil USP Related Compound G Fumarate

CAS : 1422284-15-8

Formule : C₁₇H₂₈N₅O₇P·C₄H₄O₄

Couleur et forme : White To Off-White Solid

Masse moléculaire : 445.41 116.07

Ref: 4Z-T-0213

Tenofovir Impurity 92

CAS : 1246812-40-7, 1422284-15-8

Formule : C₂₁H₂₉N₆O₅P

Couleur et forme : White To Off-White Solid

Masse moléculaire : 476.47

Ref: 4Z-T-02137

Tenofovir disoproxil

CAS : 1422284-15-8

Tenofovir disoproxil is the disoproxil fumarate salt of tenofovir. It is a nucleoside reverse transcriptase inhibitor that has been shown to be effective in the treatment of chronic hepatitis B virus (HBV) in combination with emtricitabine and as a single agent in the treatment of HIV-1 infection. Tenofovir disoproxil is available as tablets, capsules, or oral solution. The drug has been shown to cause an increase in serum creatinine levels, which may be due to inhibition of renal tubular secretion of creatinine by tenofovir. This drug should not be used with alafenamide and tenofovir because it can lead to kidney failure and death.

Formule : C₁₇H₂₈N₅O₇P·(C₄H₄O₄)

Degré de pureté : Min. 95%

Masse moléculaire : 445.41 g/mol

Ref: 3D-XGC28415

Tenofovir Disoproxil Fumarate USP Related Compound G

CAS : 1422284-15-8

Formule : C₁₇H₂₈N₅O₇PC₄H₄O₄

Masse moléculaire : 445.41 : 116.07

Ref: ST-EA-CP-T210005